stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Free cash flow
Palvella Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$25.0M, compared with −$10.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$36.5M. Over the past ten years it has ranged from −$61.0M (fiscal 2022) to $47.8M (fiscal 2017); the current reading is higher than 36% of that period. Palvella Therapeutics, Inc. ranks 299th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$25.0M | — |
| FY2024 | −$10.8M | — |
| FY2023 | −$13.9M | — |
| FY2022 | −$61.0M | — |
| FY2021 | −$8.6M | — |
| FY2020 | −$48.6M | — |
| FY2019 | −$54.9M | — |
| FY2018 | −$2.8M | — |
| FY2017 | $47.8M | — |
| FY2016 | −$14.9M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$12.8M | — |
| Mar 2026 | −$10.9M | — |
| Dec 2025 | −$4.9M | — |
| Sep 2025 | −$7.9M | — |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.0M |
| ADMA ADMA Biologics Inc compare | $140.5M |
| VCEL Vericel Corporation compare | $57.9M |
| PVLA Palvella Therapeutics, Inc. | −$36.5M |
| PHVS Pharvaris N.V. compare | −$178.1M |
| IMNM Immunome, Inc. compare | −$219.1M |
| CLDX Celldex Therapeutics, Inc. compare | −$242.1M |
| VERA Vera Therapeutics, Inc. compare | −$338.9M |
| BHVN Biohaven Ltd. compare | −$473.2M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement